UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2023

CLENE INC.

(Exact name of registrant as specified in its charter)

001-39834

(Commission File Number)

85-2828339

(IRS Employer Identification No.)

84121 (Zip Code)

(801) 676-9695

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Derecommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Derecommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value	CLNN	The Nasdaq Capital Market
Warrants, to acquire one-half of one share of Common	CLNNW	The Nasdaq Capital Market
Stock for \$11.50 per share		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Delaware (State or Other Jurisdiction of Incorporation)

6550 South Millrock Drive, Suite G50 Salt Lake City, Utah

(Address of Principal Executive Offices)

Item 2.02 Results of Operations and Financial Condition.

On May 12, 2023, Clene Inc. (the "Company") issued a press release announcing its first quarter operating and financial results for its quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933 (the "Securities Act"), as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

In connection with the May 12, 2023 press release announcing the Company's first quarter operating and financial results for its quarter ended March 31, 2023, the Company released an updated corporate presentation (the "Corporate Presentation") on its website, invest.clene.com. A copy of the Corporate Presentation is furnished as Exhibit 99.2 to this Current Report and is incorporated herein by reference. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated.

The information furnished in this Item 7.01, including Exhibit 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Description
99.1	Press Release, dated May 12, 2023, announcing the Company's operating and financial results for its quarter ended March 31, 2023.
99.2	Corporate Presentation.
104	Cover Page Interactive Data File (formatted as Inline XBRL).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: May 12, 2023

CLENE INC.

By: /s/ Robert Etherington

Robert Etherington President and Chief Executive Officer

2

CLENE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

- ALS biomarker and long-term clinical data expected mid-year
- Neurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical

SALT LAKE CITY, May 12, 2023 -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its first quarter 2023 financial results and provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS").

"Clene is approaching several important data milestones in ALS," said Rob Etherington, President and CEO of Clene. "These include key biomarker data that may support accelerated FDA approval as well as additional long-term survival data from both the HEALEY ALS Platform trial and our RESCUE ALS open-label extension trial. These data will inform our regulatory strategy as we plan ahead for our end-of-Phase 2 meeting with the FDA in the third quarter. In parallel, we are planning to advance regulatory discussions about MS anticipated in the fourth quarter and continue our pursuit of opportunities to establish a partnership for this program."

First Quarter 2023 and Recent Operating Highlights

CNM-Au8®, a gold nanocrystal suspension, for the treatment of ALS

A poster entitled "Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations" was presented on April 25th by Dr. James Berry at the American Academy of Neurology conference and included the following highlights:

- <u>Survival in Early-to-Mid Stage ALS</u>: CNM-Au8 30 mg demonstrated a statistically significant survival benefit of 60% and decreased risk of death through 120 weeks versus original placebo randomization in during follow-up of participants in the RESCUE-ALS trial.
- <u>Survival in Mid-to-late stage ALS:</u> CNM-Au8 30mg was associated with risk adjusted survival benefit of >90% and decreased risk of death through 24 weeks versus placebo in participants with mid-to-late stage ALS in the HEALEY ALS Platform trial.
- <u>Survival from real world experience in ALS:</u> CNM-Au8 30mg demonstrated observed median survival of more than three years in analyses of two compassionate use expanded access protocols.

CNM-Au8 for the treatment of MS

A platform presentation entitled "VISIONARY MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis" was presented on April 25th by Dr. Michael Barnett at the American Academy of Neurology and included the following highlights:

- The primary and secondary endpoints demonstrated improved clinical outcomes in the mITT population, independent of an immunomodulatory effect.
- The prespecified exploratory MRI findings provide evidence of brain neuronal structural integrity assessed by diffusion tensor imaging (DTI) that
 demonstrated statistically significant results for key metrics of axonal integrity and white matter integrity. Preservation of white matter integrity is generally
 associated with decreased cognitive and functional decline in MS patients.
- CNM-Au8 was well-tolerated, and no significant safety findings were observed.

Corporate Updates

- On March 3, Clene entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") pursuant to which Lincoln Park has committed to purchase up to \$25 million of shares of the Company's common stock at the Company's sole discretion, from time to time over a 36-month period.
- On March 16, Clene appointed neurology expert Benjamin Greenberg, M.D., M.H.S., as Head of Medical.

First Quarter 2023 Financial Results

Clene's cash, cash equivalents and marketable securities totaled \$18.4 million as of March 31, 2023, compared to \$23.3 million as of December 31, 2022. Clene expects that its resources as of March 31, 2023, will be sufficient to fund its operations into the third quarter of 2023.

Research and development expenses were \$7.4 million for the quarter ended March 31, 2023, compared to \$8.6 million for the same period in 2022. The year-overyear decrease was primarily related to decreases in development costs of CNM-Au8 in the HEALEY ALS Platform Trial and the REPAIR-PD and VISIONARY-MS trials due to completion of the blinded period of each trial, a decrease in development costs of CNM-ZnAg due to the completion of our COVID-19 trial in 2022, and a decrease in personnel expenses due to a reduction in headcount during the fourth quarter of 2022, partially offset by increases in rent expense for the newly-leased facility in Elkton, Maryland, and increases in stock-based compensation primarily due to the timing of award grants, vesting, and forfeitures.

General and administrative expenses were \$3.4 million for the quarter ended March 31, 2023, compared to \$4.8 million for the same period in 2022. The year-overyear decrease was primarily attributable to lower finance and accounting fees, insurance costs, legal expenses, personnel expenses and stock-based compensation.

Total other income (expense) was (\$1.0) million for the quarter ended March 31, 2023, compared to (\$18,000) for the same period in 2022. The year-over-year increase in other expense was primarily attributable to an increase in interest expense due to increasing interest rates and an increase in our overall debt balances, a gain on termination of an operating lease in 2022 that did not repeat in 2023, the expense for shares issued to Lincoln Park as an initial fee for their commitment under a purchase agreement in 2023, and a decrease in realized gains on foreign currency transactions and other miscellaneous income, offset by increased interest income primarily due to increasing rates on cash, cash equivalents and marketable investment securities.

Clene reported a net loss of \$11.8 million, or \$0.15 per share, for the quarter ended March 31, 2023, compared to a net loss of \$13.4 million, or \$0.21 per share, for the same period in 2022.

About Clene

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on <u>Twitter</u>, <u>LinkedIn</u> and <u>Facebook</u>.

About CNM-Au8®

CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8[®] is a federally registered trademark of Clene Nanomedicine, Inc.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Clene's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856

CLENE INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited)

		Three Months E	nded M	larch 31,
		2023		2022
Revenue:				
Product revenue	\$	64	\$	7
Royalty revenue		43		23
Total revenue		107		30
Operating expenses:				
Cost of revenue		5		_
Research and development		7,395		8,580
General and administrative		3,439		4,786
Total operating expenses		10,839		13,366
Loss from operations		(10,732)		(13,336)
Other income (expense), net:				
Interest income		172		24
Interest expense		(1,066)		(782)
Gain on termination of lease				420
Commitment share expense		(399)		
Change in fair value of common stock warrant liability		_		(18)
Change in fair value of Clene Nanomedicine contingent earn-out liability		(55)		(57)
Change in fair value of Initial Stockholders contingent earn-out liability		(7)		(12)
Research and development tax credits and unrestricted grants		314		299
Other income (expense), net		3		108
Total other income (expense), net		(1,038)		(18)
Net loss before income taxes		(11,770)		(13,354)
Income tax expense				_
Net loss		(11,770)	-	(13,354)
Other comprehensive income:				
Unrealized gain (loss) on available-for-sale securities		14		(50)
Foreign currency translation adjustments		4		50
Total other comprehensive income		18		
Comprehensive loss	\$	(11,752)	\$	(13,354)
Net have see the set of the set	¢	(0.15)	¢	(0.21)
Net loss per share – basic and diluted	\$	(0.15)	\$	(0.21)
Weighted average common shares used to compute basic and diluted net loss per share		76,049,665		62,852,863

CLENE INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited)


	March 31, 2023	December 31, 2022
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 18,442	\$ 18,332
Marketable securities	_	4,983
Accounts receivable	63	189
Inventory	88	43
Prepaid expenses and other current assets	6,229	5,648
Total current assets	24,822	29,195
Restricted cash	58	58
Operating lease right-of-use assets	4,494	4,602
Property and equipment, net	10,514	10,638
TOTAL ASSETS	\$ 39,888	\$ 44,493
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Accounts pavable	\$ 608	\$ 3,014
Accrued liabilities	5,933	3,863
Operating lease obligations, current portion	508	488
Finance lease obligations, current portion	76	74
Notes payable, current portion	9,751	6,418
Total current liabilities	 16,876	 13,857
Operating lease obligations, net of current portion	5,399	5,557
Finance lease obligations, net of current portion	3	34
Notes payable, net of current portion	6,713	9,483
Convertible notes payable	9,907	9,770
Clene Nanomedicine contingent earn-out liability	2,319	2,264
Initial Stockholders contingent earn-out liability	298	291
TOTAL LIABILITIES	 41,515	41,256
Commitments and contingencies		
Stockholders' equity (deficit):		
Common stock, \$0.0001 par value: 150,000,000 shares authorized; 77,987,349 and 74,759,591 shares issued and		
outstanding at March 31, 2023 and December 31, 2022, respectively	8	7
Additional paid-in capital	203,133	196,246
Accumulated deficit	(204,989)	(193,219)
Accumulated other comprehensive income	221	203
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	(1,627)	3,237
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	\$ 39,888	\$ 44,493




Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Clene's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this presentation and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our substantial dependence on the successful commercialization of our drug candidates, if approved, in the future; our inability to maintain the listing of our common stock on Nasdaq; our significant net losses and net operating cash outflows; our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our ability to obtain and maintain protection of intellectual property for our technology and drugs; our reliance on third parties to conduct drug development, manufacturing and other services; our limited operating history and our ability to obtain additional funding for operations and to complete the licensing or development and commercialization of our drug candidates; the impact of the COVID-19 pandemic on our clinical development, commercial and other operations; changes in applicable laws or regulations; the effects of inflation; the effects of staffing and materials shortages; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this presentation is as of the date of this presentation. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this presentation.


Building the Clinical Case for Neuroprotection & Remyelination




Neurodegenerative Diseases Share A Common Mechanism: A Decline In The Brain's Ability To Produce Energy




CNM-Au8[®] | Pioneering A New Drug Class To Improve Cellular Energy Production And Utilization




Significant Global Opportunity for Treatment in Combination with Standard of Care



Two REPAIR Trials Demonstrated Target Brain Engagement and Improved Energy Metabolism in Early Parkinson's and Stable Relapsing MS




RESCUEALS Encouraging Efficacy Signals in Phase 2 Trial




RESCUEALS CNM-Au8 Improved Patient Function, QOL, and Slowed Time to ALS Clinical Worsening

Phase 2 Study: 36-Week Placebo-Control Treatment Period 1:1 Randomization (Active 30 mg: Placebo); N=45 enrolled with early ALS




RESCUEALS OLE | Preserved ALSFRS-R Functional Decline


Early CNM-Au8 Treatment Impacts Long-Term Function Compared to Original Placebo



RESCUEALS OLE | Decreased ALS Time to Clinical Worsening



RESCUEALS Demonstrated Significant Impact on Long-Term Survival 60% Decreased Risk of Death through 120 weeks



Early CNM-Au8 treatment demonstrated a significant survival benefit:

- Follow-up of active compared to initial placebo randomization*
- 60% decreased risk of death

*9-month delayed treatment start (ex-placebo) or no treatment


Time to all-cause mortality amongst participants originally randomized to CNM-Au8 compared to participants originally randomized to placebo through at least 12-months following the last patient last visit (14-July-2022). Vital status and date of death (as applicable) were captured for all subjects withdrawn from the study. Lost-to-follow-up (active, n=3; placebo, n=1) censored as of the date of last study contact. All OLE ex-placebo CNM-Au8 transitioned participants within the placebo group. All current active OLE subjects are right censored as of 14-July-2022.






A Multi-center, Randomized Double-Blind, Placebo-Controlled Clinical Trial Assessing the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNM-Au8 in Participants with Amyotrophic Lateral Sclerosis

24-Week Treatment Period (3:1 randomization, 120 active [30mg, 60mg]: 40 placebo)



Survival Signal | >90% Reduced Risk of Death with 30mg







Time to Clinical Worsening Events

15

Data on File, Clene Nanor




Delayed Time to ALS Clinical Worsening (Composite)



HEALEY ALS


Platform Trial

Delayed Time to Clinical Event Summary CNM-Au8 30mg | Within Regimen Analysis (Primary Model)



HEALEY ALS Platform Trial

ALS Summary | CNM-Au8 Has Demonstrated Survival Benefit and Delayed Time to Clinical Worsening and Functional Decline



HEALEY ALS Platform Safety Summary

- Occurrence of TEAEs were balanced between CNM-Au8 and placebo
- No SAEs were assessed as related to CNM-Au8

19


Treatment Emergent Adverse Events (TEAEs)	All Shared Placebo (%)	Regimen Placebo (%)	CNM-Au8 30 mg (%)	CNM-Au8 60 mg (%)
Participants with Any TEAE	90%	93%	92%	93%
Participants with Related TEAEs	39%	34%	29%	43%
Participants with SAE	9%	17%	10%	16%
Participants with Related SAEs	1%	2%	0%	0%
Participants Withdrawn due to TEAE	7%	7%	7%	7%

All Shared Placebo (n=164 placebo from Regimens A, B, C, D); Regimen placebo (n=41) includes only concurrent randomization within Regimen C (CNM-Au8)



VISIONARY-MS Core Design Elements

Phase 2 Study: 48-Week Placebo-Control Treatment Period 2:1 Randomization (Active [15mg, 30 mg]: Placebo)



Baseline Demographics and Study Analysis


clene

- All participants diagnosed with stable relapsing remitting MS with chronic optic neuropathy
- 92% treated with background DMTs (inc 53% monoclonal antibodies, 32% oral)
- Modified ITT (mITT) Analysis Population

Baseline Value mean (sd)	Age (yrs)	Sex n, (%) Female	Race n, (%) White	Weight (kg)	EDSS Score	Years from Dx	Months Since Relapse
CNM-Au8 15 mg	38.4	15	23	78.0	1.83	6.5	53
(n=24)	(10.2)	(63%)	(96%)	(17.1)	(1.3)	(5.0)	(57)
CNM-Au8 30 mg	39.6	16	24	78.6	1.50	3.4	37
(n=25)	(7.6)	(64%)	(96%)	(17.3)	(1.1)	(3.3)	(35)
Placebo	38.1	20	22	83.0	1.85	6.6	57
(n=24)	(8.3)	(83%)	(92%)	(23.3)	(1.4)	(3.7)	(38)
All Participants	38.7	51	69	79.9	1.75	5.5	49
(n=73)	(8.6)	(70%)	(95%)	(19.3)	(1.5)	(4.3)	(45)


21

Data on File, Clene Nanomedicine, Inc.




VISIONARY-MS Measures of Axonal Integrity

VISIONARY-MS




CNM-Au8 Improved Information Signal in the Visual Pathway



VISIONARY-MS

CNM-Au8 Preserved White Matter Integrity Throughout the Brain



Summary | Consistent Paraclinical Evidence of Neuroprotective Effects Favoring CNM-Au8 Treatment

Paraclinical Endpoint	Paraclinical Measure LS Mean Change – Week 48	Significance	Key Findings	Implications	
Diffusion Tensor	FA within the whole brain (Cerebrum)	p = 0.0199	Improvements of	Neuroprotection and preservatio	
Imaging (DTI) measure of Fractional	FA within total Cerebral White Matter	p = 0.0805	axonal integrity and neuronal structure	of white matter integrity associated with decreased	
Anisotropy (FA)	FA within total Cerebral Normal Appearing White Matter	p = 0.0823	across the brain	cognitive and functional decline	
	Amplitude percent change across both eyes	p = 0.0184			
Multi-focal Visual Evoked Potential (mf- VEP)	Amplitude percent change in the most affected eye at baseline	p = 0.0730	Improved information signal along the visual pathway	Neuronal preservation and improved information signal from previously impaired neurons	
	Amplitude percent change in the least affected eye at baseline	p = 0.0047	, , , , , , , , , , , ,	prenously imported field ons	
	ical unmet need in MS for treatments that protec	t neuronal func			
	immunomodulation to decrease d	isease progress	ion		

VISIONARY-MS Safety Summary

27

Data on File, Clene Nanomedicine, Inc.

CNM-Au8 treatment was safe and well-tolerated

- Treatment emergent adverse events (TEAEs) were transient and predominantly mild-to-moderate
- No dose limiting adverse events; no related serious adverse events

Treatment Emergent Adverse Events (TEAEs)	Placebo number (%)	CNM-Au8 15 mg number (%)	CNM-Au8 30 mg number (%)
Subjects with any TEAE	22 (92%)	21 (88%)	25 (100%)
Subjects with SAE	2 (8%)	1 (4%)	2 (8%)
Subjects with Related TEAEs	2 (8%)	2 (8%)	5 (20%)
Subjects Discontinued due to TEAE	1 (4%)		1 (4%)

Placebo SAEs: (1) Lentigo maligna melanoma, (2) pregnancy; CNM-Au8 15mg SAEs: (1) Pneumonia, bacteremia (staph aureus), endocarditis; 30mg SAEs: (1) Ketamine infusion for pain and paracetamol overdose; (2) deep vein thrombosis (6-months post-discontinuation)

CNM-Au8



CNM-Au8 is Consistently Favored for Treatment of MS Progression Independent of an Immunomodulatory Effect

Significant Opportunity	 MS patients continue to progress with increasing cognitive and functional deficits accumulating even while receiving disease-modifying therapies—a significant unmet medical need
CNM-Au8® Clinica Results	 Significant improvements in clinical outcomes, brain structure, and visual system on top of immunomodulatory standard of care therapy Paraclinical MRI and VEP improvements support clinical benefits, consistently favoring CNM-Au8
Global Phase 3 MS Trial	Phase 2 VISIONARY-MS safety and efficacy results support advancement to Phase 3


VISIONARY-MS

Over 400 Years of Subject Exposure Without Identified Safety Signals Across ALS, MS, and PD


Clean Toxicology Well Tolerated **Patient Exposure Across Findings** Adverse Event (AE) Profile ALS, MS & PD All Animal Toxicology Studies Resulted in as Predominantly Mild-to-No-Adverse Effect Level (NOAEL) Findings • Multiple species up to 9-months No SAEs related to CNM-Au8 considered Long-term dosing experience up to treatment severe, life-threatening, or resulting in 175 weeks Up to maximum feasible dosing death without any toxicology findings related · AEs transient and predominantly mildto CNM-Au8 to-moderate severity

Data on File, Clene Nanomedicine, Inc. MS: Multiple Sclerosis, ALS: Amyotrophic lateral sclerosis, and PD: Parkinson's Disease.


Growing Body of Evidence for CNM-Au8°



Clene | Anticipated Catalysts Over the Next Year



Evidence Supports CNM-Au8 Therapeutic Potential to Treat Neurodegenerative Diseases





Clene Inc. HQ & Clinical Development 6550 South Millrock Drive, Suite G50 Salt Lake City, UT 84121

R&D and Manufacturing 500 Principio Parkway, Suite 400 North East, MD 21901

¹⁰2023 Clene Inc. Version: 12-May-2023